Format

Send to

Choose Destination
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1913-1920. doi: 10.1111/jdv.15733. Epub 2019 Jul 7.

Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.

Author information

1
Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.
2
Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
3
Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, the Netherlands.
4
Department of Dermatology, St Anna Ziekenhuis, Geldrop, the Netherlands.
5
Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, the Netherlands.
6
Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, the Netherlands.
7
Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, the Netherlands.
8
Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, the Netherlands.
9
Department of Dermatology, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.
10
Department of Dermatology, St Antonius Ziekenhuis, Woerden, the Netherlands.
11
Department of Dermatology, Máxima Medisch Centrum, Eindhoven, the Netherlands.
12
Radboud University, Nijmegen, the Netherlands.

Abstract

BACKGROUND:

Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear. It can be hypothesized that lower satisfaction with biological treatment in women might add to the lower drug survival rates.

OBJECTIVES:

To identify possible differences in satisfaction with biological treatment between female and male patients using the Treatment Satisfaction Questionnaire for Medication (TSQM).

METHODS:

Data of psoriasis patients treated with biologics were obtained from the prospective, multicentre, daily-practice BioCAPTURE registry. Longitudinal TSQM data were analysed by linear mixed models. Relevant patient characteristics were incorporated as possible confounding factors. Post hoc analysis of adverse events was performed in order to investigate differences between sexes.

RESULTS:

We included 315 patients with 396 corresponding treatment episodes (137 adalimumab, 90 etanercept, 137 ustekinumab, 24 secukinumab and 8 infliximab). Almost forty per cent of the patients were female. Women had significantly lower baseline PASI scores (P = 0.01). Longitudinal analyses demonstrated lower TSQM scores for 'side-effects' (P = 0.05) and 'global satisfaction' (P = 0.01) in female patients compared with male patients over 1 year of treatment. Women reported more relevant adverse events in the context of biologic treatment compared to men (rate ratio 1.79; P < 0.001), with more fungal (rate ratio 2.20; P = 0.001) and herpes simplex infections (rate ratio 3.25; P = 0.005).

CONCLUSIONS:

This study provides a prospective, longitudinal analysis of treatment satisfaction with biologics in female and male patients with psoriasis. Women were slightly less satisfied with treatment regarding side-effects and global satisfaction. Differences in treatment satisfaction and side-effects might add to the fact that women discontinue biological treatments more often.

PMID:
31177583
DOI:
10.1111/jdv.15733

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center